Lantheus Holdings, Inc. (LNTH) Operating Margin
- Operating margin · 12 months: Value 19.43%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 19.43% | Operating income / revenue. Period ending 2026-06-30. $302.34M ÷ $1.56B × 100 ≈ 19.43% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 302.34M USD | Operating Income (Loss) |
| Revenue | 1.56B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 620.29M USD | Cost of Goods and Services Sold |
| Research and development | 173.09M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $302.34M | $1.56B | $620.29M | $173.09M | (m) | 19.43% |
| 2026-03-31 | $290.09M | $1.55B | $611.00M | $180.37M | (m) | 18.76% |
| 2025-12-31 | $310.83M | $1.54B | $599.66M | $177.31M | (m) | 20.16% |
| 2025-09-30 | $347.52M | $1.53B | $576.31M | $165.15M | (m) | 22.77% |
| 2025-06-30 | $437.65M | $1.52B | $551.27M | $141.28M | (m) | 28.78% |
| 2025-03-31 | $452.41M | $1.54B | $552.55M | $156.39M | (m) | 29.44% |
| 2024-12-31 | $456.98M | $1.53B | $545.62M | $168.10M | (m) | 29.79% |
| 2024-09-30 | $480.59M | $1.50B | $527.18M | $149.60M | (m) | 32.11% |
| 2024-06-30 | $459.21M | $1.44B | $510.57M | $139.90M | (m) | 31.93% |
| 2024-03-31 | $480.62M | $1.37B | $491.31M | $95.20M | (m) | 35.19% |
| 2023-12-31 | $364.64M | $1.30B | $586.89M | $77.71M | (m) | 28.13% |
| 2023-09-30 | $55.48M | $1.21B | $558.75M | $333.11M | (m) | 4.60% |
| 2023-06-30 | $28.86M | $1.12B | $530.62M | $331.18M | (m) | 2.57% |
| 2023-03-31 | $-32.07M | $1.03B | $497.26M | $330.01M | (m) | -3.12% |
| 2022-12-31 | $36.20M | $935.06M | $353.36M | $311.68M | (m) | 3.87% |
| 2022-09-30 | $172.53M | $801.46M | $329.02M | $50.75M | (m) | 21.53% |
| 2022-06-30 | $72.46M | $664.24M | $296.56M | $49.48M | (m) | 10.91% |
| 2022-03-31 | $-17.52M | $541.58M | $265.84M | $46.81M | (m) | -3.24% |
| 2021-12-31 | $-60.83M | $425.21M | $237.51M | $44.97M | (m) | -14.30% |
| 2021-09-30 | $-26.02M | $389.80M | $221.36M | $46.31M | (m) | -6.67% |
| 2021-06-30 | $-16.94M | $376.27M | $214.24M | $46.74M | (m) | -4.50% |
| 2021-03-31 | $4.30M | $341.21M | $199.43M | $39.10M | (m) | 1.26% |
| 2020-12-31 | $-4.20M | $339.41M | $200.65M | $32.79M | (m) | -1.24% |
| 2020-09-30 | $8.77M | $334.60M | $189.93M | $24.58M | (m) | 2.62% |
| 2020-06-30 | $22.54M | $331.84M | $181.83M | $17.76M | (m) | 6.79% |
| 2020-03-31 | $42.62M | $351.53M | $182.80M | $19.14M | (m) | 12.12% |
| 2019-12-31 | $51.66M | $347.34M | $172.53M | $20.02M | (m) | 14.87% |
| 2019-09-30 | $56.17M | $344.26M | (m) | $20.14M | (m) | 16.31% |
| 2019-06-30 | $64.13M | $347.39M | (m) | $19.59M | (m) | 18.46% |
| 2019-03-31 | $65.52M | $347.25M | (m) | $18.01M | (m) | 18.87% |
| 2018-12-31 | $64.49M | $343.37M | (m) | $17.07M | (m) | 18.78% |
| 2018-09-30 | $56.75M | $338.34M | (m) | $16.50M | (m) | 16.77% |
| 2018-06-30 | $53.09M | $329.38M | (m) | $15.73M | (m) | 16.12% |
| 2018-03-31 | $55.06M | $332.65M | (m) | $16.76M | (m) | 16.55% |
| 2017-12-31 | $51.85M | $331.38M | (m) | $18.13M | (m) | 15.65% |
| 2017-09-30 | $54.79M | $324.49M | (m) | $17.86M | (m) | 16.88% |
| 2017-06-30 | $54.56M | $317.61M | (m) | $17.15M | (m) | 17.18% |
| 2017-03-31 | $50.84M | $306.74M | (m) | $14.52M | (m) | 16.58% |
| 2016-12-31 | $56.59M | $301.85M | (m) | $12.20M | (m) | 18.75% |
| 2016-09-30 | $56.84M | $298.70M | (m) | $11.56M | (m) | 19.03% |
| 2016-06-30 | $57.65M | $299.76M | (m) | $11.17M | (m) | 19.23% |
| 2016-03-31 | $48.83M | $295.11M | (m) | $11.20M | (m) | 16.54% |
| 2015-12-31 | $42.53M | $293.46M | (m) | $14.36M | (m) | 14.49% |
| 2015-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $303.09M | (m) | (m) | (m) | (m) |
| 2014-12-31 | $39.42M | $301.60M | (m) | $13.67M | (m) | 13.07% |
| 2014-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $-18.89M | $283.67M | (m) | $30.46M | (m) | -6.66% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B |